225 related articles for article (PubMed ID: 38376788)
1. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
2. Gamma-Glutamyl Transpeptidase-to-Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease.
Luo J; Du Z; Liang D; Li M; Yin Y; Chen M; Yang L
J Clin Lab Anal; 2022 Aug; 36(8):e24596. PubMed ID: 35808928
[TBL] [Abstract][Full Text] [Related]
3. AGILE SCORES IN MASLD AND ALD: EXTERNAL VALIDATION AND THEIR UTILITY IN CLINICAL ALGORITHMS.
Papatheodoridi M; De Ledinghen V; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; Delamarre A; Pinzani M; Tsochatzis EA
J Hepatol; 2024 May; ():. PubMed ID: 38789011
[TBL] [Abstract][Full Text] [Related]
4. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
[TBL] [Abstract][Full Text] [Related]
5. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
6. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC.
Lee MH; Chen YT; Huang YH; Lu SN; Yang TH; Huang JF; Yin SC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Yang HI; Chen HY; Chen CJ
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1275-1285.e2. PubMed ID: 38365094
[TBL] [Abstract][Full Text] [Related]
7. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
[TBL] [Abstract][Full Text] [Related]
8. Assessment of liver fibrosis by transient elastography and multi-parameters model in young children with chronic hepatitis B virus infection.
Luo H; Peng S; Ouyang W; Tan Y; Jiang T; Tang L; Li S; Qiu J; Zhou C
BMC Infect Dis; 2022 Feb; 22(1):160. PubMed ID: 35180839
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
Kobayashi T; Iwaki M; Nogami A; Kawamura N; Honda Y; Ogawa Y; Imajo K; Yoneda M; Saito S; Nakajima A
J Gastroenterol; 2024 Jan; 59(1):56-65. PubMed ID: 37845417
[TBL] [Abstract][Full Text] [Related]
10. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
Lee HW; Kim KH; Ahn SH; Lee HC; Choi J
Liver Int; 2024 Jun; 44(6):1448-1455. PubMed ID: 38488679
[TBL] [Abstract][Full Text] [Related]
11. Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
Fan R; Yu N; Li G; Arshad T; Liu WY; Wong GL; Liang X; Chen Y; Jin XZ; Leung HH; Chen J; Wang XD; Yip TC; Sanyal AJ; Sun J; Wong VW; Zheng MH; Hou J
Liver Int; 2024 Mar; 44(3):749-759. PubMed ID: 38131420
[TBL] [Abstract][Full Text] [Related]
12. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD.
Chouik Y; Aubin A; Maynard-Muet M; Segrestin B; Milot L; Hervieu V; Zoulim F; Disse E; Levrero M; Caussy C
Obesity (Silver Spring); 2024 Jun; 32(6):1114-1124. PubMed ID: 38699960
[TBL] [Abstract][Full Text] [Related]
13. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
[TBL] [Abstract][Full Text] [Related]
14. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
[TBL] [Abstract][Full Text] [Related]
15. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
16. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers].
Zhang XY; Qian J; Li P; Hu LH; Mi YQ
Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):332-336. PubMed ID: 29996199
[No Abstract] [Full Text] [Related]
18. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
19. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
Eur Radiol; 2023 Nov; ():. PubMed ID: 37987833
[TBL] [Abstract][Full Text] [Related]
20. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
